Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD

NCT01616680 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium as lead sponsor.

NCT NCT01616680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01616680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2012
Completion date
Not reported
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease